On November 13th, the Central Social Insurance Medical Agreement, a consulting agency of the Japanese Ministry of Health, Labour and Welfare, approved the official pricing of the new Alzheimer's disease drug "Donanemab". The annual treatment cost for a patient (assuming a weight of 50 kilograms) is approximately 3.08 million yen (about 143000 yuan). Starting from the 20th, public insurance will be applicable. The drug was developed by the American pharmaceutical giant Eli Lilly.